← back to search

Thomas J. Anchordoquy

CIBBIM-Nanomedicine · US
Area of research
Molecular Biology · Biomaterials
Research interest
Research interests include RNA Interference and Gene Delivery, Nanoparticle-Based Drug Delivery, Protein purification and stability, and Virus-based gene therapy research.
h-index
41
citations
6,728
works
103
NIH funding
primary concept
email

Recent publications

Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions
ACS Nano 2024cited by 69position: firstdoi
Reducing off-target drug accumulation by exploiting a type-III interferon response.
2023cited by 6position: contributordoi
The Effect of Repeat Administration of Lipoplexes on Gene Delivery, Biodistribution, and Cytokine Response in Immunocompetent Tumor-Bearing Mice.
2022cited by 5position: contributordoi
An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis.
2022cited by 2position: contributordoi
Addressing the Cold Reality of mRNA Vaccine Stability.
2021cited by 341position: contributordoi
Escaping to silence using an endosome-disrupting polymer.
2021cited by 1position: contributordoi
Addressing the Cold Reality of mRNA Vaccine Stability
Journal of Pharmaceutical Sciences 2020cited by 505position: middledoi
Anti-seizure therapy with a long-term, implanted intra-cerebroventricular delivery system for drug-resistant epilepsy: A first-in-man study.
2020cited by 35position: contributordoi
The Use of Lactose as an Alternative Coating for Nanoparticles.
2020cited by 7position: contributordoi
Tuning the Engines of Nanomedicine.
2020cited by 5position: contributordoi
The Potential of Exosomes From Cow Milk for Oral Delivery.
2019cited by 133position: contributordoi
A novel method for conjugating the terminal amine of peptide ligands to cholesterol: synthesis iRGD-cholesterol.
2019cited by 4position: contributordoi
Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions
ACS Nano 2017cited by 326position: firstdoi
Biodistribution and delivery efficiency of unmodified tumor-derived exosomes
Journal of Controlled Release 2014cited by 726position: lastdoi
Surface Functionalization of Exosomes Using Click Chemistry
Bioconjugate Chemistry 2014cited by 495position: lastdoi
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Drug Discovery Today 2014cited by 263position: middledoi
Questioning the use of PEGylation for drug delivery
Drug Delivery and Translational Research 2013cited by 331position: lastdoi

Grants

Collaborative: Improved Synthetic Vectors by Electrostatic Co-Extrusion
NSF0433811$254,7162005–2008PIRePORTER
Circumventing Plasmid DNA Shear-Induced Degradation
NSF0239940$181,3652002–2005PIRePORTER

Frequent collaborators

Tyson Smyth · University of Colorado Denver2 papers (2014–2014)J. Verhoef · Utrecht University2 papers (2013–2014)Michael W. Graner · University of Colorado Anschutz Medical Campus2 papers (2014–2014)Peter Smith‐Jones · Stony Brook University Hospital2 papers (2014–2014) · 1 papers (2014–2014)Daan J.A. Crommelin · Utrecht University1 papers (2020–2020) · 1 papers (2017–2017)Natalie J. Serkova · University of Colorado Anschutz Medical Campus1 papers (2017–2017)David B. Volkin · University of Kansas1 papers (2020–2020) · 1 papers (2014–2014)Wim Jiskoot · Pension Fund for Care and Well-Being1 papers (2020–2020)Huub Schellekens · Utrecht University1 papers (2014–2014)Dan Peer · Memorial Sloan Kettering Cancer Center1 papers (2017–2017) · 1 papers (2014–2014)Dorothy Farrell · Seattle University1 papers (2017–2017)Mark Cook · University of Colorado Denver1 papers (2020–2020)Michael Chorny · Columbia University1 papers (2017–2017) · 1 papers (2017–2017)Diana Boraschi · Shenzhen University1 papers (2017–2017)Max Kullberg · University of Alaska Anchorage1 papers (2014–2014)